Thomas Diacovo, MD

Expertise in: 
Neonatology
Board Certifications: 
Neonatal-Perinatal Medicine
Treats Children
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Neonatology, Pediatric Critical Care

Academic Appointments

  • Associate Professor of Pediatrics at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Credentials & Experience

Education & Training

  • McGill University Faculty of Medicine
  • Residency: Baylor Affiliated Hospitals
  • Fellowship: Children's Hospital of Boston

Board Certifications

  • Neonatal-Perinatal Medicine

Research

Clinical Trials

NCT02564718 7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis (Einstein Jr)

NCT02765633 A Prospective, Open-Label, Single-Arm, Single-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis

Grants

ANALYSIS OF PLATELET FUNCTION AND MICRORNA-MRNA PROFILES IN NEONATAL CARDIAC PATIENTS (Private)

Jul 1 2016 - Jun 30 2019

PRECLINICAL EVALUATION OF THE P2Y12 INHIBITOR CANGRELOR FOR USE IN PEDIATRIC PATIENTS (Private)

Jun 28 2013 - Jun 27 2018

TARGETING NON-CLASSICAL ONCOGENES AS THERAPY FOR T-ALL (Federal Gov)

Aug 1 2012 - May 31 2018

DEVELOPING A BIOLOGICALLY MATCHED TRANSFUSION PRODUCT FOR CRITICALLY ILL NEONATES: CORD BLOOD PLATELETS (Private)

Jul 1 2017 - Dec 31 2017

ASSESSMENT OF BIOREACTOR-DERIVED HUMAN PLATELET QUALITY, STORAGE PROFILE, SAFETY, AND FUNCTION (Federal Gov)

Apr 1 2016 - Dec 31 2017

PRECLINICAL AND CLINICAL EVALUATION OF PROTEIN KINASE INHIBITORS ON PLATELET FUNCTION (Private)

Sep 1 2014 - Aug 31 2015

GPIB ALPHA-VWF-A1 BOND KINETICS IN HEALTH AND DISEASE (Federal Gov)

Jul 1 2010 - Apr 30 2015

MULTISCALE MODEL OF PLATELET ADHESION AND THROMBUS FORMATION (Federal Gov)

Mar 8 2010 - Dec 31 2014

EVALUATING NEONATAL PLATELET FUNCTION AND RESPONSE TO ANTITHROMBOTIC AGENTS (Private)

Jul 1 2013 - Jun 30 2014

CLASS I PI3K INHIBITORS AS ADJUNCTIVE THERAPY FOR LEUKEMIA (Private)

Jul 1 2012 - Jun 30 2014

TARGETING CLASS I PI3KS IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Federal Gov)

Aug 1 2010 - Aug 31 2013

SPONSORED RESEARCH AGREEMENT WITH GILEAD (Private)

Jun 26 2012 - Jun 25 2013

CLASS I P13KS AS A THERAPEUTIC TARGET IN ACUTE LYMPHOBLASTIC LEUKEMIA (Private)

Oct 1 2009 - Sep 30 2012

EPIC (R) IMAGING LABEL FREE DETECTION PROTOTYPE SYSTEM EVALU ATION AGREEMENT (Private)

Mar 17 2011 - Mar 16 2012

SPONSORED RESEARCH AGREEMENT WITH CALISTOGA PHARMACEUTICALS, INC. (Private)

Mar 15 2011 - Mar 14 2012

EVALUATING THE EFFECTIVENESS OF M118 IN PREVENTING HUMAN PLA TELET- MEDIATED ARTERIAL THROMBOSIS AND HEMOSTASIS (Private)

Feb 9 2009 - Feb 9 2012

A NOVEL ANIMAL MODEL FOR THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP) (Private)

Jan 1 2010 - Dec 31 2011

A NOVEL BIOLOGICAL PLATFORM FOR DEVELOPMENT AND TESTING OF A NTITHROMBOTIC DRUGS AND TARGETED NON-INV (NY State Gov)

Mar 1 2008 - Oct 31 2011

P13KDELTA MODULATION OF NEUTROPHIL TRAFFICKING (Federal Gov)

Jul 1 2005 - Jul 31 2010

METHODS IN MOLECULAR IMAGING AND TARGETED THERAPEUTICS (Federal Gov)

Jul 1 2005 - Jun 30 2009

STRUCTURAL/FUNCTIONAL CHARACTERIZATION OF THE VWF-A1 DOMAIN (Federal Gov)

May 1 2000 - Apr 30 2009